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Background: Reporting of health research is often inadequate and incomplete. Complete and transparent
reporting is imperative to enable readers to assess the validity of research findings for use in healthcare and policy
decision-making. To this end, many guidelines, aimed at improving the quality of health research reports, have
been developed for reporting a variety of research types. Despite efforts, many reporting guidelines are underused.
In order to increase their uptake, evidence of their effectiveness is important and will provide authors, peer
reviewers and editors with an important resource for use and implementation of pertinent guidance. The objective
of this study was to assess whether endorsement of reporting guidelines by journals influences the completeness
of reporting of health studies.
Methods: Guidelines providing a minimum set of items to guide authors in reporting a specific type of research,
developed with explicit methodology, and using a consensus process will be identified from an earlier systematic
review and from the EQUATOR (Enhancing the QUAlity and Transparency Of health Research) Network’s reporting
guidelines library. MEDLINE, EMBASE, the Cochrane Methodology Register and Scopus will be searched for
evaluations of those reporting guidelines; relevant evaluations from the recently conducted CONSORT systematic
review will also be included. Single data extraction with 10% verification of study characteristics, 20% of outcomes
and complete verification of aspects of study validity will be carried out. We will include evaluations of reporting
guidelines that assess the completeness of reporting: (1) before and after journal endorsement, and/or (2) between
endorsing and non-endorsing journals. For a given guideline, analyses will be conducted for individual and the
total sum of items. When possible, standard, pooled effects with 99% confidence intervals using random effects
models will be calculated.
Discussion: Evidence on which guidelines have been evaluated and which are associated with improved
completeness of reporting is important for various stakeholders, including editors who consider which guidelines to
endorse in their journal editorial policies.
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Reporting guidelines
Reporting of health research is, in general, inadequate
[1-6]. Complete and transparent reporting is imperative
to assessing the validity of reported treatment effects
and other findings of health research. A study’s methods
should be described in enough detail so they can be
replicated, the analyses should follow the protocol, and
the results should be given in full enough detail to be
incorporated into future research. Complete and trans-
parent reporting enables clinicians and others to make
better, more informed health care decisions. Transparent
reporting is an integral part of the research process and
facilitates the interpretation of whether good science was
employed. For instance, without a description of the
methods used to control internal validity (for example,
randomization, blinding) and external validity (for ex-
ample, definition of the population under study), the
reader is left to guess at whether the treatment effect es-
timate reported is accurate. To ameliorate the problem
of inadequate reporting, many guidelines have been
developed, aimed at improving the quality of reports of
health research. A reporting guideline aids authors in
the reporting of specific types of research and may be
accompanied by a checklist of important items to be
reported and, potentially, a flow diagram to describe the
study process or explicit guidance text [7,8].
The EQUATOR (Enhancing the QUAlity of Transpar-
ency Of health Research) Network is an international
initiative promoting transparent and accurate reporting
of health-related research. As of October 2011, 191
reporting guidelines were indexed in the Library for
Health Research Reporting on the EQUATOR website
[9]. Of the 90 indexed in September 2009, 81 were
included in a systematic review that characterized their
development process. Guidelines in that review date
from as early as 1986 but many are more recent; ap-
proximately half were developed between 2005 and 2009
[8]. Those numbers demonstrate considerable and in-
creasing investment in the development of reporting
guidelines.
Importance for journal editors
Journals are the most important conduit for publishing
health research. Some reporting guidelines have received
positive attention, in the form of endorsement by health
journals (for example, the CONsolidated Standards Of
Reporting Trials (CONSORT) Statement is endorsed by
over 600 journals). Such endorsement is typically evi-
denced by a statement in a journal’s “Instructions to
Authors” regarding the use (suggested or required) of
one or more guidelines while preparing a study manu-
script. Some journals publish editorials indicating their
support, while others institute mandatory submission ofa guideline checklist and/or flow diagram along with
manuscript submission.
Editors are constantly striving to ensure that what is
published in their journals is, clear, complete, transpar-
ent, and as free from bias as possible. A recent survey
indicates that almost half of journal editors who
responded (n = 67) consider completeness of reporting
to be one of the top three factors when making a publi-
cation decision [10]. In the same survey, however, 18%
of the editors who were interviewed perceived endorse-
ment of a reporting guideline as burdensome. Further-
more, in an effort to uphold high standards, journal
editors may feel the need to endorse multiple reporting
guidelines without knowledge of their rigor or ability to
improve reporting. Evidence about their effect may pro-
vide editors with the rationale for making decisions
about which to endorse at their journals.
Evaluation of reporting guidelines
To date, there have been few evaluations of reporting
guidelines. In many ways reporting guidelines are a
checklist of important items that ought to be carried
out. In other fields such checklists have proven to be of
great benefit. For example, an evaluation of the World
Health Organization (WHO) Surgical Safety Checklist
showed that its implementation is associated with a 47%
reduction in the rate of death and 36% reduction in in-
patient complications after surgery [11]. Not only do
these numbers demonstrate the usefulness of a checklist
in improving mortality and morbidity in surgery, they
are arguably the most fundamental piece of information
needed to initiate change in surgical practice. Based on
these numbers, implementation of the WHO checklist is
taking place on a global scale. Similarly, checklists for
reporting research must be evaluated in order to provide
evidence for knowledge users to make informed deci-
sions about their implementation.
With respect to reporting guideline evaluation, only
17% of guideline developers report an intention to for-
mally evaluate their guidelines; 7% indicate an explicit
intention not to evaluate their guideline post-publication
[8]. In a 2008 survey of developers of 30 reporting guide-
lines, only 17% (n = 5) stated having formally evaluated
the impact of their guidelines on the completeness of
reporting of research for which it was intended [12].
These numbers demonstrate a gap between guideline de-
velopment and quality control, leaving development
efforts wasted if stakeholders are unable to judge their
effectiveness and, as such, subsequently unable to en-
dorse a guideline.
One reporting guideline that has been extensively eval-
uated is the CONSORT Statement [13-17]. In 2006, a
systematic review of CONSORT effectiveness identified
eight studies evaluating its impact [18]. A 2012 update
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[19,20]. Both found that endorsement of CONSORT by
journals is significantly associated with a higher fre-
quency of completely reported trials, at least for some
items of the CONSORT Statement. Evaluations of other
guidelines, such as the Standards for the Reporting of
Diagnostic Accuracy (STARD) statement in 2003 [21]
and the Standards for Reporting Interventions in Clinical
Trials of Acupuncture (STRICTA) Statement [22], are
known to exist but have not yet been systematically
identified and synthesized. It may be that these examples
indicate a fraction of evaluations that actually exist.
Bringing together evaluations of reporting guidelines will
provide a resource for knowledge users to aid in the
decision-making process of whether or not to implement
a reporting guideline, improve the uptake of reporting
guidelines overall, and highlight areas of reporting still
left to be evaluated.
Objectives
The objective of this systematic review is to evaluate
whether journal endorsement of reporting guidelines
influences the completeness of the reported literature by
comparing:
1. Completeness of reporting of studies published in
journals endorsing reporting guidelines before and
after endorsement.
2. Completeness of reporting of studies published in
journals that have and have not endorsed reporting
guidelines.
Methods
Criteria for including studies in this review
Types of studies
In order to identify evaluations of reporting guidelines,
we first need to determine the set of reporting guidelines
for which we will be seeking evaluations and subse-
quently, on which to base the search.
Eligibility of reporting guidelines of interest Reporting
guidelines for health research, including clinical, basic
science and laboratory research, and written only in
English, (for feasibility), will be included.
Eligibility criteria will be based on a recent systematic
review that identified and characterized the reporting
guideline process for 81 reporting guidelines for health
research [8]. Potential reporting guidelines will be
included if they contain explicit text to guide authors
in the reporting of a specific type of research (which
may or may not be accompanied by a checklist of
reporting criteria and/or a flow diagram) and if they
describe how the guideline was developed and how
consensus among the developers was obtained. Thiscriteria is intended to differentiate reporting guidelines
from other efforts in which guidance was not devel-
oped using explicit methods, even if a checklist is pro-
duced, such as the recent guidance for reporting
myeloma trials - described as ‘consensus’ in the title -
but no methods of development or consensus were
otherwise described [23]. Selection criteria will also ex-
clude guidance on the formatting of reports of health
research, such as found in some journals’ 'Instructions
to Authors’. Reporting guidelines for purposes other
than reporting research (for example, clinical case re-
port forms) will also be excluded.
For the purpose of the review, consensus is defined as
electronic communication, an online or in-person meet-
ing, a group teleconference, or the use of a Delphi
process among guideline developers. If authors provide
little to no detail about the method of consensus used
but indicate the use of consensus, it will be included, as
long as other methods of development are explicitly
described.
Where a reporting guideline has been updated over
time and several versions exist, each version will be
included as a separate reporting guideline in order to
track the number of evaluations of each.
Eligibility of evaluations of reporting guidelines Any
comparative study with the primary intent of assessing
completeness of reporting of at least one study published
in a journal that endorses reporting guidelines will be
included and considered an “evaluation” for the remain-
der; studies contained within an evaluation will be
termed “studies”. For the first comparison, evaluations
using before-after designs to compare completeness of
reporting of studies published pre- and post-
endorsement within a given journal, or cohort of jour-
nals, will be included. For the second comparison,
evaluations using a cross-sectional design to compare
completeness of reporting between studies published in
endorsing and non-endorsing journals will be included.
Evaluations examining both types of comparisons will be
included.
An editorial statement regarding the use of one or
more reporting guidelines is the minimum criterion for
a journal to be considered an “endorser”, implying that,
at least in principle, the guideline(s) is/are incorporated
into the journal’s editorial process. When included eva-
luations do not report the endorsement status of jour-
nals publishing evaluated studies (that is, it is unclear
whether studies being evaluated were published in en-
dorsing or non-endorsing journals), corresponding
authors will be contacted up to two times to provide this
information. If authors did not collect this information,
they will be asked to provide the list of studies or jour-
nals included in their evaluation; if feasible, members of
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included journals’ from “Instructions to Authors” on
their websites. If not feasible to follow-up on an author’s
list of studies or journals to obtain information on en-
dorsement status, the evaluation will be excluded with
the reason provided. Further to endorsement status, the
date of a journal’s endorsement of a reporting guideline
is important to ascertain and will help determine
whether studies in a given journal were published after a
sufficient period of time to allow for changes in editorial
policies to be realized in its publication output. For this
review, six months will be considered a reasonable
period. As it is unlikely that the date of journal endorse-
ment will be reported in evaluations, if feasible, corre-
sponding authors of evaluations or editors of evaluated
journals will be contacted for this information. If un-
available, evaluations will not be excluded on this basis;
the most recent endorsement status will be used as a
surrogate.
Evaluations using interrupted time series designs will
be excluded.
Since the CONSORT Statement is a known reporting
guideline and a systematic review of its evaluations has
recently been updated [20], data from eligible studies
will be included in this review. The search strategy of
this review intends to identify any CONSORT evalua-
tions published since the date of the last search of that
systematic review (March 2010).
Types of outcomes
Primary outcome
The primary outcome will be completeness of reporting,
This will be measured as adequate or inadequate report-
ing of any of the following surrogate outcomes, as
judged and reported in included evaluations: one or
more items in a reporting guideline checklist; a “sum-
mary score” of some or all checklist items; a flow dia-
gram (if not already included as a checklist item); or
narrative guidance found in the text.
Secondary outcomes
1. Methodological/reporting quality of an evaluation’s
included studies, as measured by any means in the
evaluation (for example, Jadad scale for randomized
controlled trials).
2. Any unwanted effect described as associated with
use of a reporting guideline (for example, increased
word count).
Methods for searching for studies
Identifying reporting guidelines of interest
Reporting guidelines included in the Moher 2011 sys-
tematic review [8], identified through a search ending inSeptember 2009, will be automatically included in this
review; guidelines were selected using the same eligibility
criteria. From October 2009 to June 2011, reporting
guidelines identified by the EQUATOR Network through
a comprehensive PubMed search (see Additional file 1:
Appendix 1 for full strategy) will be screened for poten-
tial inclusion (that is, screened using the above-listed
criteria).
Identifying evaluations of reporting guidelines
A comprehensive two-phase approach has been devel-
oped to identify evaluations of reporting guidelines.
1. Some existing reporting guidelines are formally
named using a unique acronym in their title (for
example, PRISMA: Preferred Reporting Items for
Systematic reviews and Meta-Analyses). As well,
some reporting guidelines have been widely
disseminated across multiple journals or are
accompanied by explanatory documents (for
example, CONSORT). To capture evaluations for
such guidelines, a strategy to identify evaluations
referring to any publication of a uniquely named
reporting guideline was developed. MEDLINE,
EMBASE, and the Cochrane Methodology Register
will be searched from 1990 onward using a search
strategy that includes the unique acronym of each
reporting guideline (see MEDLINE strategy in
Additional file 2: Appendix 2). This search strategy
is largely based on that used to identify evaluations
of the CONSORT Statement in the aforementioned
CONSORT systematic review [20].
2. For other reporting guidelines with commonly used
acronyms or those without acronyms, a different
approach has been developed. For instance,
“TREND” refers to guidance on the Transparent
Reporting of Evaluations with Nonrandomized
Designs but may also refer to statistical trends.
Potential evaluations of such guidelines will be
identified through forward citation searching of each
instance of a guideline’s publication in the Web
citation index, Scopus. For those guidelines,
MEDLINE and EMBASE will be searched to identify
additional, existing multiple publications to search in
Scopus.
When a reporting guideline has been updated over
time and several versions exist (for example, 1996, 2001
and 2010 versions of CONSORT), potential evaluations
of all versions will be accounted for in the search.
Reporting guideline developers will also be contacted to
ascertain knowledge of any unpublished or in-progress
evaluations. Reference lists of related systematic reviews
encountered during the screening process will also be
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evaluations detected by members of our team, publically
available before the date of the last search will be con-
sidered for inclusion.
Published and unpublished evaluations will be
included. Letters, comments and editorial publication
types will be excluded. There will be no language restric-
tion on the search strategy, but only those available in
English and French will be included, due to limited
time and resources. Potential evaluations identified in
other languages will be listed and set aside for consider-
ation at a future date. Electronic searches were peer
reviewed using the Peer Review of Electronic Search
Strategies (PRESS) Statement [24]; see Additional file 3:
Appendix 3 for peer review comments.
Data collection and analysis
Data management
Following the execution of all searches, the identified
records (titles and/or available abstracts) will be collated
in a Reference ManagerW [25] database for de-duplica-
tion. The final unique record set and full-text of
potentially eligible studies will be exported to an
Internet-based software, DistillerSRW (Evidence Partners,
Ottawa, ON, Canada), through which screening of
records will be carried out. Extraction of data from stud-
ies will be carried out in Microsoft Excel (2007, Micro-
soft Corporation, Redmond, WA, USA).
Study selection
Selecting reporting guidelines of interest
Two members of the research team will independently
apply inclusion criteria to full text reports of potential
reporting guidelines. Screening forms will be piloted
using a subset of records. Discordance between
reviewers will be resolved through consensus or by a
third team member.
Selecting evaluations of reporting guidelines
The results of the literature search will be assessed using
a two-step process:
1. One individual will screen citations by titles and/or
abstract according to the pre-specified screening
questions (level 1). For those records deemed to be
‘included’ and/or ‘unclear’, they will automatically
pass to the next level of screening (level 2).
However, if the record is deemed ‘excluded’, then it
will be assessed by a second reviewer to confirm
exclusion. This process is referred to as ‘liberal
accelerated’ screening, a more efficient means of
initially assessing records for relevancy.
2. Full-text screening will be conducted by two
independent reviewers over two phases, where pre-defined questions will be split to create two levels
(levels 2 and 3). This will be done in order to
expedite the screening process - eligibility based on
some criteria can be determined simply from the
evaluation report whereas other criteria may require
contact with corresponding authors of evaluations in
order to judge eligibility (for example, endorsement
status of journals in the evaluations). Discordance
between reviewers will be resolved through
consensus or by a third team member.
3. All screening forms will be piloted using a subset of
records. Screeners will not be blinded to study
authors or journal of publication.
Data extraction
Separate data extraction forms will be developed to cap-
ture information needed for synthesis for each of the
two comparisons of this review and will be piloted using
a subset of included evaluations and modified, as
needed. One reviewer will extract general study charac-
teristics of included evaluations, with verification of a
random 10% of studies carried out by a second reviewer.
Data on completeness of reporting for each reporting
guideline will be extracted by one reviewer; a second re-
viewer will verify the accuracy of the data from a ran-
dom 20% sample of included evaluations. Any
discrepancies between reviewers will be resolved by con-
sensus or by a third member of the research team. If
there are greater than 50% discrepancies, 100% data veri-
fication will be considered.
Data items that will be extracted from evaluations will
include:
 Name of reporting guideline being evaluated (with
version if applicable)
 Whether an included reporting guideline is an
extension of the primary reporting guideline. If so,
whether it is an official extension (that is, developed
in collaboration with primary guideline authors) will
be determined. Collaboration will be defined as
inclusion of at least one lead author of the original
guideline on the extension authorship list.
 Study design of the evaluation (for example, cross-
sectional, cohort, and so on).
 General characteristics of the evaluation: first author
name; year of publication; country of corresponding
author; corresponding author email address; source
of funding.
 Characteristics of studies assessed in the evaluation:
number of studies and publishing journals; date of
study publication; journal endorsement status and
date of journal endorsement (if available); whether
date of endorsement was determined by evaluation
authors at the time of evaluation, obtained directly
Shamseer et al. Systematic Reviews 2012, 1:24 Page 6 of 9
http://www.systematicreviewsjournal.com/content/1/1/24from journals, or determined by review authors
(based on current/surrogate status listed in journals’
“Instructions to Authors”; extent of endorsement
according to pre-defined categories (see ‘Subgroup
analysis’ section); medical specialty; guideline
checklist items assessed, if applicable.
 Completeness of reporting will be collected as
measured by any of the following surrogate
outcomes:
 Adequacy of reporting of individual checklist
items or a combination of items into a summary
score. It is anticipated that most studies will evaluate
completeness of reporting in this manner,
since 94% of reporting guidelines identified in
a recent systematic review included a checklist
[9].
 Item-by-item extraction forms will be
developed for each checklist-based reporting
guideline that is assessed in at least one
evaluation.
 Where evaluations present data on variations
of checklist items, this data will be collected
and presented in subgroup analyses (see
‘Subgroup analysis’ section).
 Calculation of a summary score may be
misleading since items within a checklist are
not necessarily of equal importance. However,
if completeness of reporting is assessed in this
manner in included evaluations, data will be
collected and analyzed.
 Adequacy of reporting according to narrative
guidance found in the text of a guideline
document.
 For evaluations of reporting guidelines without
a checklist, methods of evaluation of
completeness of reporting and overall
completeness of reporting, as reported, will be
collected.
 Adequacy of reporting other measures of
completeness of reporting, if assessed in
evaluations.
 Other measures of study quality reported in the
evaluation, however measured (for example, Jadad
scale for randomized controlled trials).
 Potential unwanted effects from using a reporting
guideline, as reported by authors of an included
evaluation, however reported.Authors of potentially included evaluations will be
contacted up to two times to obtain additional informa-
tion, if needed, such as outcome data or data not avail-
able in published reports.
Assessment of validity of included studies
One reviewer will independently assess internal validity
for each included evaluation; this will be verified by a
second reviewer. A set of criteria has been developed for
this review, based on concepts presented in the Data
Collection Checklist developed by the Cochrane Effect-
ive Practice and Organisation of Care Review Group
[26], the Strengthening the Reporting of Observational
Studies in Epidemiology (STROBE) Statement [27], the
Newcastle-Ottawa Quality Assessment Scale [28] and
the Cochrane Risk of Bias Tool [29].
Criteria for assessing validity
1. Whether more than one person evaluated
completeness of reporting of included studies
2. Whether the set of items to be evaluated (methods)
is the same as those which were evaluated (results)
3. Whether the intended set of data is completely
reported or provided
4. Whether the search strategy used to identify studies
in the evaluation was appropriate to the question
being asked
5. Whether included studies have a particular
publication frequency within included journals
6. If no to the item 5, whether confounding
considered/accounted for in the evaluation
Each criterion will be judged as yes (high validity), no
(low validity), unclear (not reported) and not applicable;
support for judgments will also be provided. As no
methods exist for synthesizing these data into a sum-
mary judgment, results of validity assessment will be
presented in tabular format for reader interpretation.
Measures of effect
The first comparison is the completeness of reporting
within endorsing journals before and after endorsement,
and the second is completeness of reporting between en-
dorsing and non-endorsing journals in the same period.
If data for both comparisons are available in a single
evaluation, the evaluation will be included in both com-
parisons (that is studies are published in endorsing and
non-endorsing journals and the endorsing cohort
includes the time periods before and after endorsement).
Within each evaluation, the proportion of studies ad-
equately reporting one or more checklist items for a
given guideline will be collected. For guidelines contain-
ing only text-based recommendations, if evaluations
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pseudo-checklist items and adequacy of reported data
will be collected for each item. A relative risk (RR) and
99% confidence intervals will be calculated for each
study; a 99% confidence interval will ensure conservative
estimates of precision are obtained. A RR> 1.0 will indi-
cate a higher proportion of studies adequately reporting
a given checklist item.
Likewise, means and standard deviations (SDs) will be
collected for checklist items combined into a summary
score; when medians and ranges are reported instead of
means and SDs, suitable approximations will be used, as
discussed in the Cochrane Handbook [30]. A standar-
dized mean difference (SMD) and 99% confidence inter-
val will be calculated for each study; an SMD>0 will
indicate more adequate reporting of checklist items con-
tained within the total summary score.
Information on the methodological quality of studies
within evaluations and any unwanted effects of reporting
guideline use will be presented as reported in the evalua-
tions. No judgments will be made on these items; they
will be presented as collected from included evaluations.
Unit of analysis
The unit of analysis in this review is an included evalu-
ation. Within each evaluation, one or more included
studies may be published in the same journal, thereby
not independent due to a common effect from editorial
policies. As such, assessment of this issue will be carried
out during validity assessment of evaluations, as
described above (see validity items 5 and 6).
Dealing with missing data
Corresponding authors of potentially included evalua-
tions will be contacted, up to two times, where data are
needed (that is endorsement status of include journals,
completeness of reporting assessments). If the data are
not obtained and compromise the ability to include the
evaluation in quantitative synthesis, they will be
excluded from the meta-analyses.
Reporting Biases
Asymmetry of funnel plots is an established method for
assessing the potential presence of publication bias in
traditional systematic reviews of intervention effective-
ness, subject to a sufficient number of included studies
[30,31]. Funnel plots are a graphical representation of in-
dividual study estimates of effect against a measure of
the study’s size or precision. In the current study, the
sample size is the number of studies included in each
evaluation. Although it is possible to generate funnel
plots to assess the potential of publication bias within
our pool of included evaluations, both the suitability and
possible interpretation of such plots are unknown.Data synthesis
For each included evaluation we will present study charac-
teristics, assessment of validity, and description of the
reporting guideline evaluations in a series of tables and a
narrative summary. Meta-analyses will be carried out
using the Review Manager [31] and Comprehensive Meta-
analysis software [32]. If evaluations for each reporting
guideline are similar enough on the basis of study design,
for each outcome, effect estimates from each evaluation
will be pooled into a single, overall, effect estimate.
Primary outcome
Pooled RRs and MDs with corresponding 99% confi-
dence intervals, using a random effects model, will be
used to compare completeness of reporting of studies
across evaluations for each checklist item or summary
score, respectively, for each guideline. Estimates of effect
for different reporting guidelines will not be pooled in
any way; subgroups and totals will be provided for each
guideline, including various versions of a given reporting
guideline, separately. Data from guidelines with only
text-based recommendations will not be pooled due to
anticipated variation in how adequacy of reporting data
was collected.
Secondary outcomes
It is expected that methods of assessment of methodo-
logical quality and reporting of unwanted effects will be
variable among included evaluations. When reported, a
descriptive summary of methodological quality of studies
included in evaluations and unwanted effects, for each
reporting guideline, will be provided. No attempt will be
made to statistically synthesize these data.
Subgroup analysis
The following subgroup analyses are planned, if feasible:
 Extent of reporting guideline endorsement by journals
included in evaluations: pre-defined groupings
developed by authors of the recent CONSORT
review will be used [20]: (a) any editorial statement
regarding use of a guideline; (b) recommendation in
a journal’s “Instructions to Authors” to follow the
guideline when preparing the manuscript; and
(c) requirement for authors to submit guideline
adherence documentation (for example, completed
CONSORT checklist) with their manuscript.
 Variations in checklist items: if variations in how
evaluations report completeness of reporting for
different checklist items are encountered, data will
be presented in the main analyses according to
different subgroups for each variation. For example,
in the CONSORT systematic review, ‘blinding’ was
reported in four different ways among evaluations
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accordingly, in the analysis [20].
 Official and unofficial extensions of reporting
guidelines: for reporting guidelines identified as
extensions to a primary guideline, effect estimates
for official and unofficial extensions will be
presented separately.
Sensitivity analyses
We plan to conduct the following sensitivity analyses, if
possible, to determine the influence on effect estimates:
 Six-month endorsement period. The primary
outcome analysis will be restricted to evaluations of
studies that were published at least six months
following the date of journal endorsement, for which
the true date of endorsement could be obtained
(that is, as provided in the report, by evaluation
authors or by journal editors, not the date on which
surrogate status was obtained by review authors).
 Study outliers. Evaluations with effect estimates
outside of the 99% CI of pooled RRs and SMDs will
be removed for sensitivity analysis.
Assessment of heterogeneity
We plan to measure the inconsistency of study results
using the I2 heterogeneity statistic to determine the ex-
tent of variation in effect estimates that is due to hetero-
geneity rather than chance. Heterogeneity, as defined by
Higgins, is measured as a percentage (%) where a value
≤25% for I2 indicates low heterogeneity, 26% to 50% indi-
cates moderate heterogeneity 51% to 75% indicates sub-
stantial heterogeneity and 76% to 100% indicates
considerable heterogeneity [30]. Substantially heteroge-
neous effect estimates will not be pooled. Possible rea-
sons for heterogeneity will be explored in sensitivity
analyses; the pre-specified subgroup analyses, if feasible,
will be examined to determine whether they provide pos-
sible reasons for any observed statistical heterogeneity.
Reporting of this review
This systematic review will be reported according to the
Preferred Reporting Items for Systematic reviews
and Meta-Analyses (PRISMA) Statement [33] – a report-
ing guideline for systematic reviews of healthcare inter-
ventions – and will include a PRISMA checklist. Where
necessary, we will adapt the reporting to ensure that all
items relevant to this review are included in the report.
Discussion
This systematic review aims to provide evidence to help
guide decision making for journal editors and publishers.
While some editors are enthusiastic about reporting
guidelines, it is likely a prudent policy to endorse andadhere to those reporting guidelines that are appropri-
ately developed and provide some evidence of effective-
ness; namely, that their use is associated with improved
completeness of reporting. The proposed systematic re-
view will provide the evidence regarding reporting
guideline effectiveness. As such we believe that we are
providing editors with evidence to help inform their pro-
spective policy about specific reporting guidelines.
Beyond journal editors we believe that the results of this
review will be of relevance to other knowledge users,
namely, peer reviewers and authors. There is an increased
interest in asking peer reviewers to use reporting guide-
lines as part of their assessment of manuscripts; 46% of
health journals surveyed (n= 116) mentioned reporting
guidelines in their instructions to peer reviewers [34]. The
results of this review will help peer reviewers decide which
reporting guidelines are effective and, thus, likely more
beneficial to use as part of the peer review process. Finally,
authors should be more strongly encouraged to use
reporting guidelines for which there is evidence that they
are associated with improved completeness of reporting.
With information summarized in this review, publish-
ers may be able to implement reporting guidelines
across a wide spectrum of journals and reduce the bur-
den on individual journals. Specifically, making reporting
guidelines accessible and required at the time of submis-
sion will greatly improve their use by authors and ease
the burden of peer-reviewing by standardizing the selec-
tion criteria across journals, specific to the research typ-
ology being reviewed.
Additional files
Additional file 1: Appendix 1. EQUATOR network Pubmed Reporting
Guidelines Search Strategy.
Additional file 2: Appendix 2. MEDLINE search strategy for evaluations
of reporting guidelines with acronyms. Searches were tailored to search
EMBASE and the Cochrane Methodology Register. Searches for remaining
reporting guidelines were conducted in Scopus.
Additional file 3: Appendix 3. PRESS EBC Search Submission.
Abbreviations
EQUATOR: Enhancing the Quallity and Transparency of health Research;
CONSORT: Consolidated Standards of Reporting Trials; STARD: Standards for
the Reporting of Diagnostic Accuracy; STRICTA: Standards for Reporting
Interventions in Clinical Trials of Acupuncture; PRISMA: Preferred Reporting
Items for Systematic reviews and Meta-Analyses; PRESS: Peer Review of
Electronic Search Strategies; STROBE: Strengthening the Reporting of
Observational Studies in Epidemiology; RR: Relative risk; SMD: Standardized
mean difference.
Competing interests
Professor Altman, and Drs. Hoey, Moher and Schulz are executive members
of the EQUATOR network; Dr. Iveta Simera and Allison Hirst are EQUATOR
staff members. The EQUATOR Network is funded by the National Health
Service (NHS) National Library of Health, NHS National Institute for Health
Research, NHS National Knowledge service, UK Medical Research Council,
Canadian Institutes of Health Research, Scottish Chief Scientist Office, Pan
American Health Organization.
Shamseer et al. Systematic Reviews 2012, 1:24 Page 9 of 9
http://www.systematicreviewsjournal.com/content/1/1/24This study is supported by a grant from the Canadian Institutes of Health
Research (#234489). CIHR had no role in study design, plans for data
collection and analysis, decision to publish, or preparation of this protocol.
Professor Altman is supported by Cancer Research UK, Dr. Moher by a
University of Ottawa Research Chair, and Dr. Schulz by FHI360. All researchers
are independent from their relevant funding agencies.
Authors contributions
LS, AS and DM have made substantial contributions to conception, design
and preparing the first draft of this protocol. All authors have contributed to
revising this protocol critically for important intellectual content and have
given final approval of the version to be published. All authors read and
approved the final manuscript.
Acknowledgements
The authors would like to thank Shona Kirtley for providing details of the
EQUATOR network search strategy for reporting guidelines and Andra
Morrison for peer reviewing the search strategies developed for this review.
Author details
1Centre for Practice-Changing Research, Ottawa Hospital Research Institute,
The Ottawa Hospital – General Campus, 501 Smyth Road, Box 201B, Ottawa,
ON K1H 8L6, Canada. 2Independent Research and Information Consultant,
Ottawa, ON, Canada. 3Centre for Statistics in Medicine, University of Oxford,
Oxford, UK. 4Queen’s University, Kingston, ON, Canada. 5St. Paul’s Hospital,
Vancouver, BC, Canada. 6FHI 360, Durham, NC, USA.
Received: 28 February 2012 Accepted: 10 April 2012
Published: 24 May 2012
References
1. Chan AW, Altman DG: Epidemiology and reporting of randomised trials
published in PubMed journals. Lancet 2005, 365:1159–1162.
2. Chan S, Bhandari M: The quality of reporting of orthopaedic randomized
trials with use of a checklist for nonpharmacological therapies. J Bone
Joint Surg Am 2007, 89:1970–1978.
3. Moher D, Tetzlaff J, Tricco AC, Sampson M, Altman DG: Epidemiology and
reporting characteristics of systematic reviews. PLoS Med 2007, 4:e78.
4. Smith BA, Lee HJ, Lee JH, Choi M, Jones DE, Bausell RB, Broome ME: Quality
of reporting randomized controlled trials (RCTs) in the nursing literature:
application of the Consolidated Standards of Reporting Trials
(CONSORT). Nurs Outlook 2008, 56:31–37.
5. Yesupriya A, Evangelou E, Kavvoura F, Patsopoulos N, Clyne M, Walsh M, Lin
BK, Yu W, Gwinn M, Ioannidis JP, Khoury MJ: Reporting of human genome
epidemiology (HuGE) association studies: an empirical assessment. BMC
Med Res Methodol 2008, 8:31.
6. Zhang D, Yin P, Freemantle N, Jordan R, Zhong N, Cheng KK: An
assessment of the quality of randomised controlled trials conducted in
China. Trials 2008, 9:22.
7. Moher D, Schulz KF, Simera I, Altman DG: Guidance for developers of
health research reporting guidelines. PLoS Med 2010, 7:e1000217.
8. Moher D, Weeks L, Ocampo M, Seely D, Sampson M, Altman DG, Schulz KF,
Miller D, Simera I, Grimshaw J, Hoey J: Describing reporting guidelines for
health research: a systematic review. J Clin Epidemiol 2011, 64:718–742.
9. EQUATOR Network: Library for health research reporting; http://www.equator-
network.org/resource-centre/library-of-health-research-reporting/.
10. Moher D: personal communication. Barriers and facilitators to CONSORT
endorsement; 2011.
11. Haynes AB, Weiser TG, Berry WR, Lipsitz SR, Breizat AHS, Dellinger EP,
Herbosa T, Joseph S, Kibatala PL, Lapitan MC, Merry AF, Moorthy K, Reznick
RK, Taylor B, Gawande AA, Safe Surgery Saves Lives Study Group: A surgical
safety checklist to reduce morbidity and mortality in a global
population. N Engl J Med 2009, 360(5):491–499.
12. Simera I, Altman DG, Moher D, Schulz KF, Hoey J: Guidelines for reporting
health research: the EQUATOR Network’s survey of guideline authors.
PLoS Med 2008, 5:e139.
13. Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, Pitkin R, Rennie D,
Schulz KF, Simel D, Stroup DF: Improving the quality of reporting of
randomized controlled trials, the CONSORT statement. JAMA 1996,
276:637–639.14. Moher D, Schulz K, Altman D, CONSORT: The CONSORT statement: revised
recommendations for improving the quality of reports of parallel group
randomized trials. BMC Med Res Methodol 2001, 1:2.
15. Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D, Gøtzsche
PC, Lang T, CONSORT GROUP (Consolidated Standards of Reporting Trials):
The revised CONSORT statement for reporting randomized trials:
explanation and elaboration. Ann Intern Med 2001, 134:663–694.
16. Schulz K, Altman D, Moher D, CONSORT Group: CONSORT 2010 Statement:
updated guidelines for reporting parallel group randomised trials. BMJ
2010, 340:c332.
17. Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ,
Elbourne D, Egger M, Altman DG: CONSORT 2010 explanation and
elaboration: updated guidelines for reporting parallel group randomised
trials. BMJ 2010, 340:c869.
18. Plint AC, Moher D, Morrison A, Schulz K, Altman DG, Hill C, Gaboury I: Does
the CONSORT checklist improve the quality of reports of randomised
controlled trials? A systematic review. Med J Aust 2006, 185(5):263–267.
19. Moher D, Plint AC, Altman DG, Schulz KF, Kober T, Galloway EK, Weeks L,
Dias S: Consolidated Standards of Reporting Trials (CONSORT) and the Quality
of Reporting of Randomized Controlled Trials (Protocol). Cochrane Database of
Systematic Reviews; 2010.
20. Turner L, Moher D, Shamseer L, Weeks L, Peters J, Plint A, Altman DG,
Schulz KF: The influence of CONSORT on the quality of reporting of
randomized controlled trials: an updated review. Trials 2011,
12(suppl 1):A47.
21. Smidt N, Rutjes AWS, Van der Windt D, Ostelo R, Bossuyt PM, Reitsma JB,
Bouter LM, de Vet HC: The quality of diagnostic accuracy studies since
the STARD statement: has it improved?. Neurology 2006, 67:792–797.
22. Prady SL, Richmond SJ, Morton VM, MacPherson H: A systematic
evaluation of the impact of STRICTA and CONSORT recommendations
on quality of reporting for acupuncture trials. PLoS One 2008, 3:e1577.
23. Rajkumar SV, Harousseau J, Durie B, Anderson KC, Dimopoulos M, Kyle R,
Blade J, Richardson P, Orlowski R, Siegel D, Jagannath S, Facon T, Avet-
Loiseau H, Lonial S, Palumbo A, Zonder J, Ludwig H, Vesole D, Sezer O,
Munshi NC, San Miguel J, International Myeloma Workshop Consensus
Panel 1: Consensus recommendations for the uniform reporting of
clinical trials: report of the International Myeloma Workshop Consensus
Panel 1. Blood 2011, 117:4691–4695.
24. Sampson M, McGowan J, Cogo E, Grimshaw J, Moher D, Lefebvre C: An
evidence-based practice guideline for the peer review of electronic
search strategies. J Clin Epidemiol 2009, 62(9):944–952.
25. Reference Manager; 2008.
26. Cochrane Effective Practice and Organisation of Care Review Group (EPOC):
Data Collection Checklist; 2002.
27. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke
JP, STROBE Initiative: Strengthening the Reporting of Observational
Studies in Epidemiology (STROBE) statement: guidelines for reporting
observational studies. BMJ 2007, 335:806–808.
28. Wells GB, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P: The
Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised
studies in meta-analyses. Liverpool, UK: University of Liverpool; 2000.
29. Higgins JPT, Altman DG: Assessing risk of bias in included studies. In
Cochrane Handbook for Systematic Reviews of Interventions. 510th edition.
Edited by Higgins JPT, Green S: The Cochrane Collaboration; 2008:187–242.
30. Deeks JJ, Higgins JPT, Altman DG: Analysing data and undertaking meta-
analyses. In Cochrane Handbook for Systematic Reviews of Interventions. 510th
edition. Edited by Higgins JPT, Green S: The Cochrane Collaboration; 2011.
31. The Cochrane Collaboration, Review Manager (RevMan). 2011; 5.1.
32. Borenstein M, Hedges L, Higgins J, Rothstein H: Comprehensive
Meta-analysis. 2005.
33. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group: Preferred
reporting items for systematic reviews and meta-analyses: the PRISMA
statement. BMJ 2009, 339:b2535.
34. Hirst A, Altman DG: Are peer reviewers encouraged to use reporting
guidelines? A survey of 116 health research journals. PLoS ONE 2012, 7(4):
e35621. doi:10.1371/journal.pone.0035621.
doi:10.1186/2046-4053-1-24
Cite this article as: Shamseer et al.: Does journal endorsement of
reporting guidelines influence the completeness of reporting of health
research? A systematic review protocol. Systematic Reviews 2012 1:24.
